This HTML5 document contains 83 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00752/identifier/pubchem-substance/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/AHFS/
n17http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00752/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/mixture/
n25http://bio2rdf.org/drugbank:
n23http://linked.opendata.cz/resource/drugbank/drug/DB00752/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00752/identifier/wikipedia/
n5http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n19http://www.rxlist.com/cgi/generic2/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00752/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/property/
n4http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00752/identifier/pdb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00752/identifier/kegg-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00752/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00752
rdf:type
n5:Drug
n5:description
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
n5:dosage
n12:271B57FE-363D-11E5-9242-09173F13E4C5 n12:271B57FF-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Frieling H, Bleich S: Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16927039 # Nolen WA: [Classical monoamine oxidase inhibitor: not registered for, but still a place in the treatment of depression] Ned Tijdschr Geneeskd. 2003 Oct 4;147(40):1940-3. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14574774
n5:group
approved
n5:halfLife
1.5-3.2 hours in patients with normal renal and hepatic function
n5:indication
For the treatment of major depressive episode without melancholia.
n5:manufacturer
n17:271B57F8-363D-11E5-9242-09173F13E4C5 n17:271B57F9-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00752 n25:DB00752
dcterms:title
Tranylcypromine
adms:identifier
n15:Tranylcypromine n20:1LP n21:PA451741 n22:C07155 n23:390008 n24:DB00752 n27:441233 n28:46505832
n5:mechanismOfAction
Tranylcypromine irreversibly and nonselectively inhibits monoamine oxidase (MAO). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms, as this results in an increase in the concentrations of these amines within the CNS.
n5:packager
n17:271B57F4-363D-11E5-9242-09173F13E4C5 n17:271B57F5-363D-11E5-9242-09173F13E4C5 n17:271B57F3-363D-11E5-9242-09173F13E4C5 n17:271B57F6-363D-11E5-9242-09173F13E4C5 n17:271B57F7-363D-11E5-9242-09173F13E4C5
n5:synonym
Tranylcypromin Tranylcypromine Tranilcipromina Transamine Tranylcyprominum Parnate
n5:toxicity
In overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.
n5:volumeOfDistribution
1.1-5.7 L/kg
n7:hasAHFSCode
n8:28-16-04-12
n5:foodInteraction
Avoid aged foods (chesse, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician. Avoid St. John's Wort. Avoid alcohol. Avoid excessive quantities of coffee or tea (caffeine).
n5:mixture
n26:271B57F1-363D-11E5-9242-09173F13E4C5 n26:271B57F2-363D-11E5-9242-09173F13E4C5
n5:salt
foaf:page
n4:par1618.shtml n18:tranylcypromine.html n19:tranylcypromine.htm
n5:IUPAC-Name
n6:271B5804-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B580A-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5809-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5806-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5807-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5808-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5802-363D-11E5-9242-09173F13E4C5 n6:271B5819-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5800-363D-11E5-9242-09173F13E4C5 n6:271B5803-363D-11E5-9242-09173F13E4C5 n6:271B581B-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5801-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n16:N06AF04
n5:H-Bond-Acceptor-Count
n6:271B5810-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5811-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B580B-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B580C-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B580E-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B580D-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B580F-363D-11E5-9242-09173F13E4C5
n5:absorption
Interindividual variability in absorption. May be biphasic in some individuals. Peak plasma concentrations occur in one hour following oral administration with a secondary peak occurring within 2-3 hours. Biphasic absorption may represent different rates of absorption of the stereoisomers of the drug, though additional studies are required to confirm this.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
155-09-9
n5:category
n5:containedIn
n9:271B57FC-363D-11E5-9242-09173F13E4C5 n9:271B57FD-363D-11E5-9242-09173F13E4C5 n9:271B57FA-363D-11E5-9242-09173F13E4C5 n9:271B57FB-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B5815-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5817-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5818-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B581A-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5814-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5813-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5816-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5805-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5812-363D-11E5-9242-09173F13E4C5